New
HealthMore in Health →
Phase 3 CRISPR Success Gives Gene Editing a New Clinical Milestone
Intellia Therapeutics says a gene-editing treatment for hereditary angioedema succeeded in Phase 3, marking what the company describes as the first Phase 3 CRISPR readout and a consequential step for the field.
Key Takeaways
- Intellia says its gene-editing treatment for hereditary angioedema succeeded in Phase 3.
- The result is framed as the company’s first Phase 3 CRISPR readout, making it a significant field milestone.
DE
DT Editorial AI··via endpoints.news